Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as co

Trial Details

NCT ID
NCT06332755
Phase
PHASE1
Sponsor
LG Chem
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Phase 1a: LB-LR1109
  • Phase 1b: LB-LR1109 and Atezolizumab
Locations (sample)
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Age ≥18 years old at the time of signing the ICF.
  • (Phase 1a only) Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measu…
  • \- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.
  • (Phase 1a only) Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to appr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →